Dicoumarol down-regulates human PTTG1/Securin mRNA expression through inhibition of Hsp90

Molecular Cancer Therapeutics

Volumn 7, Issue 3, 2008, Pages 474-482

  Hernández, Agustín ^a,b   López Lluch, Guillermo ^a   Bernal, Juan A ^a,c   Navas, Plácido ^a   Pintor Toro, José A ^a,b  

^a UNIVERSIDAD PABLO DE OLAVIDE   (Spain)

^b CSIC   (Spain)

^c HUTCHISON MRC RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DICOUMAROL; HEAT SHOCK PROTEIN 90; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; NOVOBIOCIN; RAF PROTEIN; RAS PROTEIN; SECURIN; TANESPIMYCIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOASSAY; CANCER CELL; CONTROLLED STUDY; DOWN REGULATION; DRUG HYPERSENSITIVITY; GENE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; INHIBITION KINETICS; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PROTO ONCOGENE; SECURIN GENE; SIGNAL TRANSDUCTION;

ANTICOAGULANTS; APOPTOSIS; BASE SEQUENCE; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL LINE, TUMOR; DICUMAROL; DNA PRIMERS; DOWN-REGULATION; FLOW CYTOMETRY; GENE SILENCING; HSP90 HEAT-SHOCK PROTEINS; HUMANS; NEOPLASM PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 41649098631     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-0457     Document Type: Article

References (48)

1. Tfelt-Hansen J, Kanuparthi D, Chattopadhyay N. The emerging role of pituitary tumor transforming gene in tumorigenesis. Clin Med Res 2006;4:130-7.
2. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33:49-54.
3. Hlubek F, Pfeiffer S, Budczies J, et al. Securin (hPTTG1) expression is regulated by β-catenin/TCF in human colorectal carcinoma. Br J Cancer 2006;94:1672-7.
4. Clem AL, Hamid T, Kakar SS. Characterization of the role of Sp1 and NF-Y in differential regulation of PTTG/Securin expression in tumor cells. Gene 2003;322:113-21.
5. Vlotides G, Cruz-Soto M, Rubinek T, Eigler T, Auernhammer CJ, Melmed S. Mechanisms for growth factor-induced pituitary tumor transforming gene-1 (PTTG1) expression in pituitary folliculostellate TtT/GF cells. Mol Endocrinol 2006;20:3321-35.
6. Bernal JA, Luna R, Espina A, et al. Human Securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis. Nat Genet 2002;32:306-11.
7. Zhou Y, Mehta KR, Choi AP, Scolavino S, Zhang X. DNA damage-induced inhibition of Securin expression is mediated by p53. J Biol Chem 2003;278:462-70.
8. Duxbury BM, Poller L. The oral anticoagulant saga: past, present, and future. Clin Appl Thromb Hemost 2001;7:269-75.
9. Brar SS, Kennedy TP, Whorton AR, et al. Reactive oxygen species from NAD(P)H:quinone oxidoreductase constitutively activate NF-κB in malignant melanoma cells. Am J Physiol Cell Physiol 2001;280:C659-76.
10. Du J, Daniels DH, Asbury C, et al. Mitochondrial production of reactive oxygen species mediate dicoumarol-induced cytotoxicity in cancer cells. J Biol Chem 2006;281:37416-26.
11. Hosoda S, Nakamura W, Hayashi K. Properties and reaction mechanism of DT diaphorase from rat liver. J Biol Chem 1974;249:6416-23.
12. Cross JV, Deak JC, Rich EA, et al. Quinone reductase inhibitors block SAPK/JNK and NFκB pathways and potentiate apoptosis. J Biol Chem 1999;274:31150-4.
13. Pratt WB, Toft DO. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood) 2003;228:111-33.
14. Broemer M, Krappmann D, Scheidereit C. Requirement of Hsp90 activity for IκB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-κB activation. Oncogene 2004;23:5378-86.
15. Georgakis GV, Li Y, Younes A. The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9. Br J Haematol 2006;135:68-71.
16. Bagatell R, Whitesell L. Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther 2004;3:1021-30.
17. Chinnaiyan P, Allen GW, Harari PM. Radiation and new molecular agents. Part II. Targeting HDAC, HSP90, IGF-1R, PI3K, and Ras. Semin Radiat Oncol 2006;16:59-64.
18. Marcu MG, Schulte TW, Neckers L. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J Natl Cancer Inst 2000;92:242-8.
19. Yu XM, Shen G, Neckers L, et al. Hsp90 inhibitors identified from a library of novobiocin analogues. J Am Chem Soc 2005;127:12778-9.
20. 2 arrest after DNA damage. Science 1998;282:1497-501.
21. Benitah SA, Valeron PF, Lacal JC. ROCK and nuclear factor-κB- dependent activation of cyclooxygenase-2 by Rho GTPases: effects on tumor growth and therapeutic consequences. Mol Biol Cell 2003;14:3041-54.
22. Schneider C, Sepp-Lorenzino L, Nimmesgern E, et al. Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. Proc Natl Acad Sci U S A 1996;93:14536-41.
23. Louvion JF, Abbas-Terki T, Picard D. Hsp90 is required for pheromone signaling in yeast. Mol Biol Cell 1998;9:3071-83.
24. Gietz RD, Woods RA. Yeast transformation by the LiAc/SS Carrier DNA/PEG method. Methods Mol Biol 2006;313:107-20.
25. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 1989.
26. Zhu L, van den Heuvel S, Helin K, et al. Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein. Genes Dev 1993;7:1111-25.
27. 1 peak. Cytometry 1987;8:1-8.
28. Aoufouchi S, Shall S. Regulation by phosphorylation of Xenopus laevis poly(ADP-ribose) polymerase enzyme activity during oocyte maturation. Biochem J 1997;325:543-51.
29. Karczewski JM, Peters JG, Noordhoek J. Quinone toxicity in DT-diaphorase-efficient and -deficient colon carcinoma cell lines. Biochem Pharmacol 1999;57:27-37.
30. Ramos-Morales F, Dominguez A, Romero F, et al. Cell cycle regulated expression and phosphorylation of hpttg proto-oncogene product. Oncogene 2000;19:403-9.
31. Sun SC, Ganchi PA, Ballard DW, Greene WC. NF-κB controls expression of inhibitor IκBα: evidence for an inducible autoregulatory pathway. Science 1993;259:1912-5.
32. D'Odorico A, Sturniolo GC, Bilton RF, Morris AI, Gilmore IT, Naccarato R. Quinone-induced DNA single strand breaks in a human colon carcinoma cell line. Carcinogenesis 1997;18:43-6.
33. Rosenhagen MC, Soti C, Schmidt U, et al. The heat shock protein 90-targeting drug cisplatin selectively inhibits steroid receptor activation. Mol Endocrinol 2003;17:1991-2001.
34. Thompson AD III, Kakar SS. Insulin and IGF-1 regulate the expression of the pituitary tumor transforming gene (PTTG) in breast tumor cells. FEBS Lett 2005;579:3195-200.
35. Vasilevskaya IA, O'Dwyer PJ. Effects of geldanamycin on signaling through activator-protein 1 in hypoxic HT29 human colon adenocarcinoma cells. Cancer Res 1999;59:3935-40.
36. Hsu HY, Tan SK, Li VP, Wang WT, Cheng CH, Hsu J. Geldanamycin interferes with Hsp90, affecting LPS-mediated IL-1 expression and apoptosis within macrophages. Mol Pharmacol 2006;71:344-56.
37. Kanakis D, Kirches E, Mawrin C, Dietzmann K. Promoter mutations are no major cause of PTTG overexpression in pituitary adenomas. Clin Endocrinol (Oxf) 2003;58:151-5.
38. Chamaon K, Kirches E, Kanakis D, Braeuninger S, Dietzmann K, Mawrin C. Regulation of the pituitary tumor transforming gene by insulin-like-growth factor-I and insulin differs between malignant and non-neoplastic astrocytes. Biochem Biophys Res Commun 2005;331:86-92.
39. Bian X, Opipari AW, Jr., Ratanaproeksa AB, Boitano AE, Lucas PC, Castle VP. Constitutively active NFκB is required for the survival of S-type neuroblastoma. J Biol Chem 2002;277:42144-50.
40. Smirnov AS, Ruzov AS, Budanov AV, Prokhortchouk AV, Ivanov AV, Prokhortchouk EB. High constitutive level of NF-κB is crucial for viability of adenocarcinoma cells. Cell Death Differ 2001;8:621-30.
41. D'Angiolella V, Santarpia C, Grieco D. Oxidative stress overrides the spindle checkpoint. Cell Cycle 2007;6:576-9.
42. Panopoulos A, Harraz M, Engelhardt JF, Zandi E. Iron-mediated H2O2 production as a mechanism for cell type-specific inhibition of tumor necrosis factor α-induced but not interleukin-1β-induced IκB kinase complex/nuclear factor-κB activation. J Biol Chem 2005;280:2912-23.
43. Debatin KM. Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immunother 2004;53:153-9.
44. Mosser DD, Morimoto RI. Molecular chaperones and the stress of oncogenesis. Oncogene 2004;23:2907-18.
45. de Carcer G. Heat shock protein 90 regulates the metaphase-anaphase transition in a polo-like kinase-dependent manner. Cancer Res 2004;64:5106-12.
46. Kawase M, Sakagami H, Motohashi N, et al. Coumarin derivatives with tumor-specific cytotoxicity and multidrug resistance reversal activity. In Vivo 2005;19:705-11.
47. Bertram J, Palfner K, Hiddemann W, Kneba M. Increase of P-glycoprotein-mediated drug resistance by Hsp90β. Anticancer Drugs 1996;7:838-45.
48. Marcu MG, Chadli A, Bouhouche I, Catelli M, Neckers LM. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J Biol Chem 2000;275:37181-6.